레타스피마이신

레타스피마이신
레타스피마이신 구조식 이미지
카스 번호:
857402-23-4
한글명:
레타스피마이신
동의어(한글):
레타스피마이신
상품명:
Retaspimycin
동의어(영문):
retamycin;retaspimycin;Unii-bzf2zm0I5z;18,21-Didehydro-17-demethoxy-18,21-dideoxo-18,21-dihydroxy-17-(2-propenylamino)geldanamycin;Geldanamycin, 18,21-didehydro-17-demethoxy-18,21-dideoxo-18,21-dihydroxy-17-(2-propen-1-ylamino)-
CBNumber:
CB31518530
분자식:
C31H45N3O8
포뮬러 무게:
587.7
MOL 파일:
857402-23-4.mol

레타스피마이신 속성

끓는 점
800.9±65.0 °C(Predicted)
밀도
1.23
저장 조건
Store at -20°C
용해도
DMSO에 용해됨
물리적 상태
가루
산도 계수 (pKa)
10.15±0.70(Predicted)

안전

레타스피마이신 C화학적 특성, 용도, 생산

개요

Retaspimycin is a small-molecule inhibitor of heat shock protein 90 (HSP90) with antiproliferative and antineoplastic activities. Retaspimycin binds to and inhibits the cytosolic chaperone functions of HSP90, which maintains the stability and functional shape of many oncogenic signaling proteins and may be overexpressed or overactive in tumor cells. Retaspimycin-mediated inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins in susceptible tumor cell populations, which may result in the induction of apoptosis.

용도

Retaspimycin (IPI-504) was previously under development by manufacturer Infinity Pharmaceuticals in conjunction with MedImmune, a part of AstraZeneca. Retaspimycin is a small-molecule inhibitor of heat shock protein 90 (HSP90) with antiproliferative and antineoplastic activities. Retaspimycin binds to and inhibits the cytosolic chaperone functions of HSP90, which maintains the stability and functional shape of many oncogenic signaling proteins and may be overexpressed or overactive in tumor cells. Retaspimycin-mediated inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins in susceptible tumor cell populations, which may result in the induction of apoptosis. Orphan drug designation was assigned to the compound by the FDA for the treatment of gastrointestinal stromal cancer (GIST). Infinity Pharmaceuticals has discontinued the development of retaspimycin (IPI-504) an inhibitor of the HSP-90) complex, for the treatment of cancer due to lack of efficacy in 1913.

정의

ChEBI: An ansamycin that is tanespimycin in which the benzoquinone moiety has been reduced to the corresponding hydroquinone. A semi-synthetic analogue of geldanamycin, it is used (generally as the hydrochloride salt) in cancer treatment.

생물학적 활성

IPI-504 potently inhibits proliferation in several tumor cell lines with 50% inhibition concentration IC50 values ranging from 10-40 nM and has been used for the treatment of gastrointestinal stromal tumors, soft-tissue sarcomas and non-small cell lung cancer.

레타스피마이신 준비 용품 및 원자재

원자재

준비 용품


레타스피마이신 공급 업체

글로벌( 39)공급 업체
공급자 전화 이메일 국가 제품 수 이점
TargetMol Chemicals Inc.
+1-781-999-5354 +1-00000000000
marketing@targetmol.com United States 19892 58
Career Henan Chemica Co
+86-0371-86658258 +8613203830695
laboratory@coreychem.com China 30253 58
Baoji Guokang Bio-Technology Co., Ltd.
0917-3909592 13892490616
gksales1@gk-bio.com China 9322 58
Hangzhou MolCore BioPharmatech Co.,Ltd.
+86-057181025280; +8617767106207
sales@molcore.com China 49739 58
Shaanxi Cuikang Pharmaceutical Technology Co., Ltd
+86-19164747840 +86-13119157289
13119157289@163.com China 2971 58
Amadis Chemical Company Limited
571-89925085
sales@amadischem.com China 131980 58
Chembest Research Laboratories Limited 021-20908456
sales@BioChemBest.com China 6008 61
Jinan Mingya Medical Technology Co., Ltd. 0531-85828981
864598798@qq.com China 588 58
Codow Chemical Co.,Ltd. 18620099427
amy@howeipharm.com China 17698 55
Chengdu Dianchun Technology Co., Ltd 400-1166-196 18502815961
cdhxsj@163.com China 14623 60

Copyright 2019 © ChemicalBook. All rights reserved